Billionaire Israel and England put their money into 2 “strong buy” stocks
After experiencing the frenzy of 2020, where does the market come from? Significant progress has been made in the COVID-19 vaccine race, but the near-term prospects are still unclear due to the virus’s recovery and the irritating deadlock on Capitol Hill. The source of inspiration is the billionaire Israeli “Izzy”
; Englishman. Who are the Englishmen? The legendary man started trading stocks in high school. He started his career as an intern at the investment company Oppenheimer and later bought a seat on the American Stock Exchange, where he will serve as a floor broker, trader and expert. In 1989, Englander and Ronald Shear co-founded the hedge fund Millennium Management. As evidence of its outstanding performance, the master took away 35 million US dollars when the fund was founded and turned it into assets under management of more than 40 billion US dollars. Given his personal net worth of US$7.2 billion, Wall Street will not pay attention to it when the Englishman takes action. With this in mind, our focus has shifted to Millenium’s recent 13F filing, which discloses The fund’s shares snapped up in the third round. 25 cent coin. TipRanks’ database specifically locks two stocks, both of which have received unanimous praise from analysts for “Strong Buy”. In addition, the analyst community believes that each drug has huge upside potential. G1 Therapeutics (GTHX) has a deep understanding of cancer biology and extensive drug discovery experience. G1 Therapeutics is committed to developing therapies that may improve the lives of patients who fight deadly diseases. Before an important regulatory decision, Wall Street was knocking on the table with this name. In the third quarter, the Englishman and Millennium acquired new shares in GTHX. Needham’s Chad Messer told us that the trigger price in 555,937 shares is $6,421,000. Needham’s Chad Messer told the client that he has high hopes for PDUFA’s trilaciclib on February 15th. Trilaciclib’s treatment aims to improve the outcome. Cancer patients are treated with chemotherapy. According to the results of three randomized clinical studies for small cell lung cancer (SCLC), the NDA of this therapy was accepted for priority review in August, and the FDA said it does not plan to hold an advisory committee (AdComm) meeting. Messer believes that the lack of AdComm, the first CDK4/6 inhibitor to treat chemically-induced bone marrow toxicity, is “meaningful.” He elaborated on this, “We think this reflects the agency’s unmet needs, the comfort of CDK4/6 category safety and the appreciation of trilaciclib.” GTHX will also work to include trilaciclib in NCCN. Guidelines. It is worth mentioning that a pivotal Phase 3 study evaluating drug candidates for metastatic colorectal cancer (mCRC) will be launched at the end of the year. The company has approximately 2500 therapeutic oncologists and provides educational materials on the use of Trilaciclib before treatment and the benefits of multi-lineage preservation. If it is not enough, it is rintodestant (its selective estrogen receptor degradant (SERD)) Messer believes that it is under development for the treatment of estrogen receptor positive (ER +) breast cancer patients, plus palbociclib combined research Recruitment can be completed earlier than expected, reflecting the “attractiveness of all oral treatment options during the global pandemic.” Analysts are expected to release data in the second quarter of 2021, so “positive readings may prove to be an important value driver.” Messer reiterated his optimism, reiterating a buy rating and a price target of $74, indicating that The stock has 417% upside potential. (To view Messer’s track record, click here) Do other analysts agree? they are. Only 3 exact “buy” ratings have been published in the last three months. Therefore, the message is clear: GTHX is a strong buy. Taking into account the average price target of 59 dollars, the company’s stock may rise 312% next year. (See GTHX stock analysis on TipRanks) Epizyme (EPZM) In order to fight cancer and other serious diseases, Epizyme also hopes to find new treatments through new epigenetic drugs. Although the company has encountered resistance in the recently launched products, some members of Wall Street still believe that things are brewing. Millenium purchased 461,258 shares in the third quarter, reflecting the new position of the hedge fund. As for the holding value, it reached $5,503,000. Wedbush’s five-star analyst David Nierengarten pointed out that this pandemic restricts visits by oncologists and therefore sales of Tazverik (the company’s follicular lymphoma treatment) The amount is lower than his expectations. . He pointed out that “the pandemic shifts the emission curve into an “incidence model” rather than a prevalence model, because if the time for consultation is delayed, there will be a limited patient population to choose from,” patients wait to seek treatment until they experience another Although the launch is virtual and physician awareness is high, physicians are opposed to prescribing new drugs without personally checking patients. Having said that, Nigengarten is still optimistic about the therapy. “Despite these unfavorable factors, Tazverik is still close to our expectations and is gaining market share, including seeing initial sales of second-line drugs. Analysts explained that we expect second-line sales to begin to be more meaningful in 2021 and gradually Incorporate them into our listing curve. Speaking of the timing of treatment, Nielsen Garten believes that it is too early to draw conclusions. However, he emphasized the fact that the response is relatively long-lasting and is in the registration study The patient received more treatment than progressed. “In addition, once the patient receives treatment, the unfavorable factors against switching therapy will become unfavorable factors for Tazverik’s maintenance. He added that this will likely make a more meaningful contribution to 2H21 revenue and potential revenue performance. To sum up, “At the current level, we believe that investors are too negative about Tazverik’s potential and should be patient.” Among them, Nierengarten maintained a long position, reiterating its outperform rating and a target price of $27. This goal expresses his confidence in EPZM’s ability to climb 122% next year. (To view Nilengarten’s track record, please click here). Most other analysts echo Nilengarten’s views. Three buys and one position are added together to get a “Strong Buy” consensus rating. The average target price is US$23.25 and the upside potential is 91%. (See EPZM stock analysis on TipRanks) To find a good idea for healthcare stocks that trade at attractive valuations, visit TipRanks’ Best Buys Buy, a newly launched tool that combines All stock insights from TipRanks. Limited to those analysts with characteristics. The content is for reference only. Before making any investment, it is very important to conduct your own analysis.